Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-02-14, Stock:LLY, The news for the past five days is as follows:
2018-02-07: NEWS1: Read This Before Buying Eli Lilly and Company (NYSE:LLY) For Its Upcoming $0.56 Dividend.NEWS2: Here's What Was Behind Nektar Therapeutics Stupendous 40% Jump in January.NEWS3: Here's What Was Behind Nektar Therapeutics Stupendous 40% Jump in January.NEWS4: Array's Melanoma Combo Shows Positive Overall Survival Data.NEWS5: Array's Melanoma Combo Shows Positive Overall Survival Data.
2018-02-08: NEWS1: Pfizer Reports Revenue Growth in 4Q17.NEWS2: Vanguard Health Care Fund's Largest Sales of the 4th Quarter.NEWS3: How Amgen Performed in 4Q17.NEWS4: The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease.NEWS5: Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices.NEWS6: Today’s Research Reports on Trending Tickers: Eli Lilly and Company and InspireMD.NEWS7: See what the IHS Markit Score report has to say about Eli Lilly And Co..
2018-02-09: NEWS1: Solid Q4 Earnings Drive Pharma ETF Outlook.NEWS2: Solid Q4 Earnings Drive Pharma ETF Outlook.NEWS3: Solid Q4 Earnings Drive Pharma ETF Outlook.NEWS4: A Look at Amgen’s Nplate, Vectibix, and Neupogen in 4Q17.NEWS5: See what the IHS Markit Score report has to say about Eli Lilly And Co..NEWS6: How Amgen’s Xgeva and Prolia Performed in 4Q17.
2018-02-12: NEWS1: Bristol-Myers Squibb’s Oncology Portfolio in 4Q17.NEWS2: Can Jakafi Performance Drive Incyte's (INCY) Q4 Earnings?.NEWS3: Can Jakafi Performance Drive Incyte's (INCY) Q4 Earnings?.NEWS4: Analyst Recommendations for Amgen in February 2018.NEWS5: What’s Pfizer’s Valuation after 4Q17 Earnings?.NEWS6: [$$] Buying United, Selling Lilly, Rambus, Tronc.NEWS7: Today’s Research Reports on Trending Tickers: Eli Lilly and Company and Pfizer.NEWS8: See what the IHS Markit Score report has to say about Eli Lilly And Co..NEWS9: Better Buy: Pfizer Inc. (PFE) vs. Eli Lilly (LLY).NEWS10: Better Buy: Pfizer Inc. (PFE) vs. Eli Lilly (LLY).NEWS11: Better Buy: Pfizer Inc. (PFE) vs. Eli Lilly (LLY).
2018-02-13: NEWS1: Dodge & Cox Comments on Eli Lilly.NEWS2: Dodge & Cox 4th Quarter Commentary.NEWS3: Health Care Sector Update for 02/13/2018: ABC,WBA,LLY,BDX,DARE.NEWS4: Health Care Sector Update for 02/13/2018: ABC,WBA,LLY,BDX,DARE.NEWS5: Health Care Sector Update for 02/13/2018: DARE,LLY,BDX.NEWS6: Health Care Sector Update for 02/13/2018: DARE,LLY,BDX.NEWS7: How Pfizer Performed Overall in 4Q17 and 2017.NEWS8: Pfizer Announces FDA Acceptance of NDA for NSCLC Candidate.NEWS9: Pfizer Announces FDA Acceptance of NDA for NSCLC Candidate.NEWS10: Better Buy: Eli Lilly and Company vs. Johnson & Johnson.NEWS11: Better Buy: Eli Lilly and Company vs. Johnson & Johnson.NEWS12: Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for February 14, 2018.NEWS13: Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for February 14, 2018.NEWS14: Health Care Sector Update for 02/13/2018: JNJ, PFE, ABT, MRK, AMGN, ABC, GNC, LLY, DARE, HCM, CLLS, BDX.NEWS15: Health Care Sector Update for 02/13/2018: JNJ, PFE, ABT, MRK, AMGN, ABC, GNC, LLY, DARE, HCM, CLLS, BDX.NEWS16: Better Buy: Eli Lilly and Company vs. Johnson & Johnson.NEWS17: Eli Lilly's Taltz meets primary endpoint in late-state trial for AS treatment.NEWS18: Lilly Announces Positive Top-Line Phase 3 Results for Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis).NEWS19: Eli Lilly: Taltz Phase 3 Study Meets Endpoints To Treat Ankylosing Spondylitis.NEWS20: Eli Lilly: Taltz Phase 3 Study Meets Endpoints To Treat Ankylosing Spondylitis.

Answer: Rise